In the News
Medpage Today
January 27, 2025
An immunotherapy combination for advanced, highly mutated colorectal cancer (CRC) significantly slowed disease progression versus a single drug, according to a randomized study.
Cancer Network
January 27, 2025
The major pathologic response rate improved with extended time to surgery using botensilimab plus balstilimab in resectable colorectal cancer.
OncLive
January 25, 2025
Balstilimab and botensilimab combination therapy showed superior efficacy in MSS mCRC patients without liver metastases compared to botensilimab monotherapy.
Manufacturing Today
December 20, 2024
Harnessing the power of the immune system, Agenus Bio leads the charge in immuno-oncology.